EMA Authorised: Vaniqa (eflornithine) — Almirall, S.A.

View source ↗

Summary

The European Medicines Agency authorised Vaniqa (eflornithine) for the treatment of hirsutism. The marketing authorisation holder is Almirall, S.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hirsutism

Drugs mentioned

• Vaniqa (eflornithine)

Snippet

Status: Authorised. Therapeutic area: Hirsutism. MAH: Almirall, S.A.. Decision date: 29/10/2024